PE41796A1 - Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. - Google Patents

Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.

Info

Publication number
PE41796A1
PE41796A1 PE1995278830A PE27883095A PE41796A1 PE 41796 A1 PE41796 A1 PE 41796A1 PE 1995278830 A PE1995278830 A PE 1995278830A PE 27883095 A PE27883095 A PE 27883095A PE 41796 A1 PE41796 A1 PE 41796A1
Authority
PE
Peru
Prior art keywords
optionally substituted
alkyl
hydrogen
substituted phenyl
diseases
Prior art date
Application number
PE1995278830A
Other languages
English (en)
Inventor
Peter Thaddeus Gallagher
Martin Victor Miles
Jeremy Gilmore
William Martin Owton
Colin William Smith
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418326A external-priority patent/GB9418326D0/en
Priority claimed from GBGB9511166.2A external-priority patent/GB9511166D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of PE41796A1 publication Critical patent/PE41796A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gyroscopes (AREA)

Abstract

SE REFIERE AL COMPUESTO DE FORMULA I DONDE: R1 Y R7 SON CADA UNO HALO, TRIFLUROMETILO, ALQUILO DE C1-C6 ENTRE OTROS; R2 Y R3 SON CADA UNO HIDROGENO o ALQUILO DE C1-C6; R4 Y R5 SON CADA UNO HIDROGENO, HALO, TRIFLUOROMETILO ENTRE OTROS; R6 ES HIDROGENO, ALQUILO DE C1-C6, FENILO OPCIONALMENTE SUSTITUIDO ENTRE OTROS; m Y p SON CADA UNO DE CERO A CUATRO, DE PREFERENCIA m ES DE CERO A DOS; n ES DE UNO A CUATRO, DE PREFERENCIA ES UNO O DOS; Z ES >N-R9, -O-, -S- ENTRE OTROS, DE PREFERENCIA EL PRIMERO; DONDE R9 ES H, ALQUILO DE C1-C6 ENTRE OTROS; X ES OXIGENO O AZUFRE, DE PREFERENCIA OXIGENO; Y ES >N-C-R11R12 o -CR11R12-N<; DONDE R11 Y R12 SON CADA UNO H, ALQUILO DE C1-C6, TRIFLUOROMETILO ENTRE OTROS. ESTE COMPUESTO ES USADO EN EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
PE1995278830A 1994-09-12 1995-09-12 Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c. PE41796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418326A GB9418326D0 (en) 1994-09-12 1994-09-12 Pharmaceutical compounds
GBGB9511166.2A GB9511166D0 (en) 1995-06-02 1995-06-02 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PE41796A1 true PE41796A1 (es) 1996-10-21

Family

ID=26305611

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995278830A PE41796A1 (es) 1994-09-12 1995-09-12 Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.

Country Status (22)

Country Link
EP (1) EP0705832B1 (es)
JP (1) JPH0881464A (es)
KR (1) KR960010635A (es)
CN (1) CN1045602C (es)
AT (1) ATE247114T1 (es)
AU (1) AU698580B2 (es)
CA (1) CA2157998A1 (es)
CZ (1) CZ286565B6 (es)
DE (1) DE69531476T2 (es)
ES (1) ES2204932T3 (es)
FI (1) FI954243A (es)
HU (1) HU219491B (es)
IL (1) IL115236A (es)
IN (1) IN179550B (es)
MY (1) MY132009A (es)
NO (1) NO305174B1 (es)
NZ (1) NZ272961A (es)
PE (1) PE41796A1 (es)
PH (1) PH31631A (es)
PL (1) PL310373A1 (es)
RU (1) RU2146256C1 (es)
TR (1) TR199501114A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0905136A1 (en) 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
AU7887501A (en) * 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
JP5062939B2 (ja) * 2000-09-19 2012-10-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
JP5062938B2 (ja) * 2000-09-19 2012-10-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
ES2250689T3 (es) 2001-08-08 2006-04-16 PHARMACIA &amp; UPJOHN COMPANY LLC 1h-pirido(4,3-b)indoles terapeuticos.
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
JP2011006409A (ja) * 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035369A (en) 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
CA2157998A1 (en) 1996-03-13
CZ286565B6 (cs) 2000-05-17
CZ232295A3 (en) 1996-03-13
EP0705832B1 (en) 2003-08-13
NO953575L (no) 1996-03-13
IN179550B (es) 1997-10-18
FI954243A (fi) 1996-03-13
IL115236A (en) 1998-06-15
CN1045602C (zh) 1999-10-13
PL310373A1 (en) 1996-03-18
NO953575D0 (no) 1995-09-11
IL115236A0 (en) 1995-12-31
EP0705832A1 (en) 1996-04-10
PH31631A (en) 1999-01-12
ATE247114T1 (de) 2003-08-15
KR960010635A (ko) 1996-04-20
AU698580B2 (en) 1998-11-05
MY132009A (en) 2007-09-28
JPH0881464A (ja) 1996-03-26
CN1129219A (zh) 1996-08-21
DE69531476T2 (de) 2004-06-09
HU9502631D0 (en) 1995-11-28
ES2204932T3 (es) 2004-05-01
RU2146256C1 (ru) 2000-03-10
HUT72593A (en) 1996-05-28
FI954243A0 (fi) 1995-09-11
HU219491B (hu) 2001-04-28
NO305174B1 (no) 1999-04-12
NZ272961A (en) 1998-02-26
AU3049795A (en) 1996-03-28
TR199501114A2 (tr) 1996-10-21
DE69531476D1 (de) 2003-09-18

Similar Documents

Publication Publication Date Title
PE41796A1 (es) Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.
SE9904176D0 (sv) New use
ES512842A0 (es) &#34;procedimiento de preparar derivados carboxamidicos&#34;.
HUP0300693A2 (hu) Eljárás epotilon-analógok és -intermedierek előállítására
CO5271691A1 (es) Nuevos compuestos
SE0301446D0 (sv) New Compounds
ATE202774T1 (de) Benzoxazepinverbindungen, ihre herstellung und verwendung als lipidsenker
ES2078297T3 (es) Piridazinaminas antipicornaviricas.
NO20000737L (no) Tetrahydro &lt;gamma&gt;-karboliner
DE69706386D1 (de) 2-Aryl-3-Aminoaryloxynaphthylverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren
DE69603667T2 (de) Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
MX25922A (es) Pirido (3,4-b) pirrolo (1,2-e)(1,4,5)oxadiazepinasy compuestos analogos relacionados un procedimiento para su preparacion y su uso como medicamentos
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
NO972942L (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
FR2823749B1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed